RaySearch Laboratories AB/Skr RAY B
1D1W1MYTD1Y5YMAX
Capital at risk
About RaySearch Laboratories AB
RaySearch Laboratories AB is a medical technology company based in Sweden that specializes in software solutions for radiation therapy used in cancer treatment. The company's primary product is RayStation, an advanced treatment planning system that integrates a comprehensive set of tools for creating radiation therapy plans. Founded in 2000, RaySearch focuses heavily on research and development to innovate in adaptive therapy, automated planning, and machine learning. Its strategic partnerships with major equipment vendors expand its geographic presence, serving clinics and hospitals worldwide. The company's competitive strength lies in its advanced algorithms and focus on improving patient outcomes and treatment workflows.
- Ticker
- Skr RAY B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 464
- Headquarters
- Stockholm, Sweden
- Website
- www.raysearchlabs.com
RAY B Metrics
BasicAdvanced
kr 5.8B
27.61
kr 6.23
0.92
kr 4.00
2.33%
Price and volume
Market cap
kr 5.8B
Beta
0.92
52-week high
kr 267.00
52-week low
kr 153.10
Average daily volume
199K
Dividend rate
kr 4.00
Financial strength
Current ratio
1.288
Quick ratio
1.225
Long term debt to equity
0.356
Total debt to equity
0.456
Dividend payout ratio (TTM)
64.37%
Interest coverage (TTM)
35.69%
Profitability
EBITDA (TTM)
344.3
Gross margin (TTM)
93.02%
Net profit margin (TTM)
16.77%
Operating margin (TTM)
24.73%
Effective tax rate (TTM)
21.49%
Revenue per employee (TTM)
kr 2,740,000
Management effectiveness
Return on assets (TTM)
10.32%
Return on equity (TTM)
26.02%
Valuation
Price to earnings (TTM)
27.613
Price to revenue (TTM)
4.632
Price to book
7.38
Price to tangible book (TTM)
29.51
Price to free cash flow (TTM)
33.437
Free cash flow yield (TTM)
2.99%
Free cash flow per share (TTM)
5.144
Dividend yield (TTM)
2.33%
Forward dividend yield
2.33%
Growth
Revenue change (TTM)
1.39%
Earnings per share change (TTM)
10.73%
3-year revenue growth (CAGR)
10.36%
10-year revenue growth (CAGR)
11.01%
3-year earnings per share growth (CAGR)
59.58%
10-year earnings per share growth (CAGR)
8.47%
10-year dividend per share growth (CAGR)
31.95%
Bulls say / Bears say
Order intake rose 23% in Q2, reflecting sustained demand despite licensing headwinds (Reuters)
Recurring support revenue increased to SEK 133 million (49% of sales), providing revenue stability amid fluctuations (Reuters)
Secured nine RayStation orders worth approximately USD 5 million in July, including one from University of North Carolina School of Medicine, indicating recovery of delayed business (Reuters)
Net sales fell 11% y/y to SEK 272 million in Q2 due to postponed U.S. orders, signaling weakness in its core market (Reuters)
Operating profit declined 22% to SEK 28 million, with margins narrowing to 10% from 12%, reflecting margin pressure (Reuters)
CEO acknowledged two consecutive quarters of U.S. deal delays, underscoring ongoing execution risks in a critical region (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Upcoming events
No upcoming events
Funds containing RAY B
AllUSDEURGBP
Fund name | Fund size | Skr RAY B weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.06% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.06% |
iShares Healthcare Innovation£DRDR | £1B | 0.06% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.03% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.